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Abstract
Development of small molecular kinase inhibitors has recently been the central focus in drug discovery. And type II kinase
inhibitors that target inactive conformation of kinases have attracted particular attention since their potency and selectivity
are thought to be easier to achieve compared with their counterpart type I inhibitors that target active conformation of
kinases. Although mechanisms underlying the interactions between type II inhibitors and their targeting kinases have been
widely studied, there are still some challenging problems, for example, how type II inhibitors associate with or dissociate
from their targeting kinases. In this investigation, steered molecular dynamics simulations have been carried out to explore
the possible dissociation pathways of typical type II inhibitor imatinib from its targeting protein kinases c-Kit and Abl. The
simulation results indicate that the most favorable pathway for imatinib dissociation corresponds to the ATP-channel rather
than the relatively wider allosteric-pocket-channel, which is mainly due to the different van der Waals interaction that the
ligand suffers during dissociation. Nevertheless, the direct reason comes from the fact that the residues composing the ATP-
channel are more flexible than that forming the allosteric-pocket-channel. The present investigation suggests that a bulky
hydrophobic head is unfavorable, but a large polar tail is allowed for a potent type II inhibitor. The information obtained
here can be used to direct the discovery of type II kinase inhibitors.
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Introduction
Protein kinases are enzymes essential for cell signal transduc-
tion, which regulate a variety of physiological processes including
metabolic, cell cycle, apoptosis and cell differentiation [1–3].
Dysregulation of protein kinases might lead to some pathological
changes, for example, cancer, diabetes, and various autoimmune
diseases [4,5]. Thus protein kinases have been thought as central
targets for drug discovery. In the past decade, extensive efforts
have been made to develop protein kinase inhibitors as potential
drugs against a wide range of diseases [6–13]. And it is believed
that understanding of issues related to the protein kinase
structures, mechanisms underlying enzyme activation and the
kinase-inhibitor interaction could benefit the discovery of novel
kinase inhibitors.
All protein kinases share a common catalytic domain, which
contains two subdomains: the N-terminal lobe and the C-terminal
lobe [14]. The two lobes are connected through a flexible chain
(hinge region). The natural substrate ATP is bound in the cleft
between the two lobes (the ATP binding pocket). The active loop
(A-loop), which belongs to the C-terminal lobe but locates outside
of the ATP-binding pocket, directly regulates the enzyme
activation through its conformational changes. Majority of small
molecule kinase inhibitors reversibly occupy the ATP binding
pocket, which means that they are ATP-competitive inhibitors.
The ATP-competitive inhibitors can be further classified into two
categories, type I and type II [15,16]. Type I inhibitors target the
active form of the kinases, in which the A-loop adopts an extended
conformation. Such conformational arrangement of A-loop
completely exposes the ATP-binding pocket, hence facilitating
the entry/exit of ATP or type I inhibitors (this entry/exit pathway
will be called as traditional ATP-channel hereafter, see Figure 1A).
Type II inhibitors target the inactive form of kinases and bind to
an extended ATP-binding site, in contrast to type I inhibitors. In
the inactive form, the A-loop crimples outside of the ATP-binding
pocket. This conformation of A-loop shrinks the original entry/
exit gate, which hinders the access of ATP and protein substrates
to the kinase catalytic site. Another concomitant conformational
change is the flip of DFG-motif that locates in the beginning of A-
loop, which opens a new hydrophobic pocket (usually called
allosteric pocket) in the back of the protein [17] (see Figure 1B).
Type II inhibitors often occupy both the original ATP-binding
pocket and the allosteric pocket. It appears that there are two
possible pathways for the entry/exit of type II inhibitors: one is the
traditional ATP-channel and the other one is the allosteric-pocket-
channel. Now, a question arises that which one is preferred. X-ray
crystal structures of kinase-inhibitor complexes show that the
allosteric-pocket-channel might be favored since this channel is
relatively wider than the ATP-channel [18,19]. This hypothesis,
however, is inconsistent with the fact that many receptor tyrosine
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to the gate of allosteric-pocket-channel in the inactive form of
kinases. Even so, our previous study on the JMR dynamics did not
deny the allosteric-pocket-channel of type II inhibitors [20]. In
order to clarify this mechanism, we need to use molecular
dynamics simulations, which is mainly due to the fact that the
dissociation of ligands from targeting proteins is governed by the
dynamic behavior of ligand-protein complexes that is difficult to
handle experimentally.
In this account, steered molecular dynamics (SMD) simulations
[21–23] will be employed to explore the possible dissociation
channel for type II kinase inhibitors from inactive form of kinases.
Despite several methods of molecular dynamics simulations that
are currently available for handling this type of rare events (see the
section of Models and Methods), SMD has been seen as the most
suitable method to address the binding/unbinding issues of
biomolecules [24–30]. (A brief description about the SMD
algorithm, as well as its advantages and disadvantages compared
with other approaches, will be given in the section of Models and
Methods). Here, we chose imatinib (see Figure 2A) as our model of
type II kinase inhibitors; imatinib is the first type II protein kinase
inhibitor on the market and has become a reference compound for
the kinase community. The cellular targets of imatinib include the
Abl/Bcr-Abl protein kinase that is involved in the development of
chronic myeloid leukaemia (CML) [31], the c-Kit kinase that is
implicated in gastrointestinal stromal tumours (GIST) [32,33].
Thanks to the advance of structural biology, the crystal structures
of c-Kit and Abl in complex with imatinib have been available
[18,19] (see Figure 2B and 2C). Another important reason why we
chose both c-Kit and Abl protein kinases as our models is that c-
Kit and Abl represent two distinct regulation modes of catalytic
activation. Abl is a typical cytoplastic kinase, which activation
depends directly on the phosphoralation of TYR412 on A-loop
[34]. Contrastively, c-Kit is a typical receptor tyrosine kinase,
which activation depends on not only the phosphoralation of the
A-loop but also the JMR (TYR1-ASP33) [20,35]. Since JMR
locates around the gate of allosteric-pocket-channel, it seems that
the JMR could have some impact on the entry/exit of ligand. In a
word, we expected that SMD simulations could provide us with
more insights into the entry/exit mechanism of type II inhibitors
from the inactive form of protein kinases. We also believe that a
detailed understanding of the entry/exit dynamics will ultimately
help with the design of new type II kinase inhibitors.
Methods
Computational Models
The initial structures for imatinib-c-Kit and imatinib-Abl com-
plexes were prepared based on their corresponding X-ray crystal
structures (PDB entry is 1T46 for imatinib-c-Kit and 2HYY for
imatinib-Abl). The unresolved residues in imatinib-c-Kit, including
TYR547-ASN564, ILE690-THR694, SER753-GLU761, HIS934-
ILE935, were constructed by using the homology modeling module
Modeler within InsightII (Accelrys, San Diego, CA), in which
the reference protein structure was taken from the PDB code 1T45.
Steered Molecular Dynamics Simulations
SMD is an extended MD simulation method that mimics the
basic idea of atomic force microscopy (AFM). SMD allows
exploring the binding and unbinding properties of a variety of
biomolecules as well as their responses to external mechanical
manipulations at the atomic level [36,37]. It is particularly suitable
for the investigation of dissociation of a ligand from its binding
protein. In such case, a ligand is forcedly pulled out of the binding
site of a given protein along the route that is specified in advance.
The pulling force F is applied according to the following equation:
F(t)~k½vt{(~ r r{~ r r0):~ n n ð 1Þ
where k is the force constant, v is the pulling velocity, ~ n n is the
pulling direction normal,~ r r and~ r r0 are the position of ligand at time
Figure 1. Typical three-dimensional structures of protein
kinases shown in Ca ribbon fashion. (A) is for active conformation,
and (B) for inactive conformation. Key structural components of the
protein are color coded: A-loop in red, helix aC in purple, others in gray.
Type I (for the active conformation) and type II (for the inactive
conformation) kinase inhibitors are schematically shown in green wire
mesh.
doi:10.1371/journal.pone.0008470.g001
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pathway, the (~ r r{~ r r0) increases and the force decreases; if the
pulling force can not displace the ligand, the force will increase
because of the increase of t. So, it is possible to draw a profile to
express the force required to dissociate the ligand as the function of
simulation time, and hence determine the difficulty to dissociate
ligand along the different pathway.
Actually several methods that utilize the principles of molecular
dynamics to investigate this type of rare processes have been
developed. In these methods, some external perturbations are
applied to the system in order to accelerate the dynamic process
and guide the system toward a target state. Such methods typically
include, for examples, targeted molecular dynamics (TMD)
[38,39] and biased molecular dynamics (BMD) [40,41], in
addition to SMD used here. The TMD methodology imposes a
time-dependent holonomic or harmonic constraint on the RMSD
(root mean square deviation) in order to drive the system to a
target structure. BMD provides the least perturbation compared
with SMD and TMD, in which the system feels no external force if
it moves toward the target and the biasing potential is nonzero
only if the system moves away from the target.
In contrast to TMD and BMD, SMD closely resembles the
AFM experiment. In addition, the exact target structure is not
necessary to know in advance for SMD simulations. These make
the SMD very suitable to be used for exploring the dynamics
behaviors of binding/unbinding processes of biomolecules.
Although SMD provides an approach to investigate the bind-
ing/unbinding events, yet the pulling direction of the force in
SMD is chosen randomly or by guessing on the basis of structural
information, which makes that the force applied to the ligand in
such chosen directions may not move it along a favorable
pathway. In order to overcome this shortcoming, a generally used
strategy is to perform a series of SMD simulations with different
directions of pulling force. Dynamic properties of the system can
be obtained by averaging those of all the individual simulations.
This strategy has also been used in this investigation, which will be
mentioned again later.
Computational Details
All the simulations, including conventional molecular dynamics
simulations (CMD) which purpose was to make the model systems
to reach their thermodynamic equilibration states, and SMD, were
carried out using the programs NAMD 2.6 [42] with constant
molecular number, pressure, and temperature (NPT) and periodic
boundary conditions. The CHARMM 27 force field [43,44] was
employed for the protein and the gaff force field [45] for imatinib.
The model systems were solvated in a bath of TIP3P water
molecules [46] with the buffering distance set to 15 A ˚ which is
large enough for the conformational changes. By assuming normal
charge states of ionizable groups corresponding to pH 7, sodium
(Na
+) and chloride (Cl
2) counter-ions at physiological concentra-
tion of 0.15 mol?L
21 were added in the box in random positions
to ensure the global charge neutrality. All Na
+ and Cl
2 ions were
placed more than 8 A ˚ away from any protein atoms and from
each other.
Constant temperature (T=310 K) and constant pressure (P=1
bar) were maintained using Langevin piston coupling algorithm
[47]. The integration time step of the simulations was set to 2.0 fs,
the SHAKE algorithm was used to constrain the lengths of all
chemical bonds involving hydrogen atoms at their equilibrium
values [48], and the water geometry was restrained rigid by using
the SETTLE algorithm [49]. Non-bonded van der Waals
interactions were treated by using a switching function at 10 A ˚
and reaching zero at a distance of 12 A ˚. Long-range electrostatic
Figure 2. Chemical structure of imatinib and its binding modes
to c-Kit and Abl. (A) Chemical structure of imatinib. (B) 3D structure of
imatinib-c-Kit complex (PDB entry: 1T46). (C) 3D structure of imatinib-
Abl complex (PDB entry: 2HYY). In (B) and (C), protein structures are in
Ca ribbon fashion and imatinib in green CPK fashion. Key structural
components of the protein are color coded: A-loop in red, helix aCi n
purple, JMR in blue, others in gray.
doi:10.1371/journal.pone.0008470.g002
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algorithm [50], which is an efficient full electrostatics method for
use with periodic boundary conditions.
The systems were firstly minimized using steepest-descents
algorithm. Afterward, the systems were heated from 0 K to 310 K
in two steps: the first step was a 100ps heating process with the
protein and ligand fixed; the second step was another 100 ps
heating process with the whole system relaxed. Thirdly, a 200 ps
CMD simulation was performed with the protein and ligand fixed,
followed by a 4 ns CMD simulation with the whole system
relaxed. The SMD simulations were then performed, in which
initial structures were the snapshots randomly taken from the
equilibration states in the CMD simulations. The acting point of
pulling point for the ATP-channel is the mass center of pyridine
group of imatinib, and that for the allosteric-pocket-channel is the
mass center of piperazinyl group of imatinib. The harmonic
constraints were applied to the Ca atoms of helix in the Abl and c-
Kit and the exponent to be used in the harmonic constraint energy
functions was 2. The force constant and velocity used in the SMD
simulations are 4 kcal mol
21 A ˚ 22 (277.9 pN A ˚ 21) and 0.00005 A ˚
timestep
21 (0.025A ˚ ps
21), respectively.
By the way, it is necessary to point out that the affinity of the
ligand for the two pockets can not be directly given by the force
measurements in the current SMD simulations, although SMD
provides a possibility to calculate the binding affinity by, for
example, applying the Jarzynski equality [36]. This is mainly due
to that (1) the system concerned here experiences a large
conformational change, and (2) the SMD simulations here are
still very limited. To obtain the ligand binding affinity, a much
larger set of simulations are required. Fortunately, the calculation
of ligand binding affinity is not necessory for the objective in this
investigation that is to explore the possible dissociation pathways
of typical type II inhibitor imatinib from its targeting protein
kinases c-Kit and Abl.
Results and Discussion
Dissociation of Imatinib from c-Kit
Before performing SMD simulations to pull imatinib out of c-
Kit, 4 ns CMD simulation was first carried out which purpose
was to make the whole system equilibrated at the designated
temperature. Figure 3 shows the variations of RMSD values for
the Ca atoms of JMR (TYR1-ASP33), A-loop (CYS205-
LEU227) and the remaining regions (RR, that are all the
residues of c-Kit except those in JMR and in A-loop), relative to
the crystal structure during the MD simulations. Obviously, in
the beginning, the RMSD values for the JMR have a significant
change, which is understandable since JMR is a loop and
completely exposed to the solvent. In contrast to JMR, a small
fluctuation of RMSD values is observed for A-loop and RR.
After 3 ns, the RMSD values for the whole system fluctuate
steadily, implying that the whole system reaches its equilibration
state.
After that, ten snapshots were randomly chosen from the
equilibration state (3ns–4ns) as the initial structures for the
subsequent SMD simulations, with five snapshots for each
pathway (ATP-channel or allosteric-pocket-channel). Before
executing the actual SMD simulations, all the possible directions
for the pulling force were identified based on the relative
orientation of ligand and its binding site. Then five independent
SMD simulations for each pathway were performed, in which the
direction of pulling force was randomly chosen in the range of
possible directions just identified.. The simulation time for each
SMD simulation is 1 ns.
Figure 4A presents the profiles of pulling force during the SMD
simulations for the ATP-channel. Clearly, increased force appears
when the ligand imatinib begins to move out of the binding site,
irrespective of initial structure and the direction of pulling force,
which imply that the ligand encounters energy barriers. The
maximum pulling forces for the ATP-channel are between 737–
1080 pN, and averaged at 816 pN (see Figure 4C). Finally the
pulling force becomes to zero, indicating that the ligand
completely dissociated from c-Kit. The pulling force profiles for
dissociation along the allosteric-pocket-channel are shown in
Figure 4B. Very similar to the ATP-channel, the forces increase in
the beginning of ligand unbinding, and reaches a maximum
around 0.4 ns, followed by returning to zero.
Visibly, the ligand suffers a smaller force when dissociation
along the ATP-channel than through the allosteric-pocket-
channel. Quantitatively, the maximum average force along the
ATP-channel is 816 pN, which is smaller by 19% than that along
the allosteric-pocket-channel (1008 pN). The integrated forces
shown in Table 1 reflect even clearer how dissociation is easier
along ATP-channel: the total force required for the ligand to be
extracted is 332 pN?ns, which is 16% smaller than that in
allosteric-pocket-channel (397 pN?ns).
What are the determining factors to result in that the ligand
dissociation along the allosteric-pocket-channel is difficult than
the ATP-channel? Here one may simply think that the JMR,
which locates outside of the allosteric-pocket-channel, might be the
most important factor. Thus, in order to further explore this
matter, another model system, namely, imatinib-Abl, in which Abl
is a cytoplastic kinase, was chosen to perform the same SMD
simulation. Since no JMR in the Abl kinase, imatinib-Abl is
expected to be a good model to judge the role of JMR.
Dissociation of Imatinib from Abl
Again a 4 ns CMD simulation was firstly performed in order to
make the imatinib-Abl equilibrated in the solvent at the designated
temperature. Figure 5 depicts the variation of the RMSD values
relative to the initial structure for the Ca atoms of A-loop
(ALA146-PRO168) and the remaining regions (RR, that are all
the residues of Abl except those in A-loop). Clearly, after 2.5 ns,
the RMSD values for A-loop, RR, and hence the overall system,
Figure 3. RMSD (root mean square deviation) profiles of key
motifs in imatinib-c-Kit complex during conventional molecu-
lar dynamics simulation. The reference structure from which the
RMSD was calculated is the crystal structure 1T46.
doi:10.1371/journal.pone.0008470.g003
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Similarly, we selected randomly ten snapshots in the equilibra-
tion state as the initial structures for the SMD simulations. Five of
them are for the ATP-channel and the other five for the allosteric-
pocket-channel. Figure 6A and 6B show the pulling force profiles
for dissociation along the ATP-channel and allosteric-pocket-
channel, respectively. For both pathways, the pulling forces
increase in the beginning of ligand unbinding process, irrespective
of initial structure and the direction of pulling force, indicating
again that the ligand encounters energy barriers. Finally the
pulling forces return to zero, denoting that the ligand completely
dissociated from the Abl.
Comparisons of the force profiles for both pathways show that
the maximum pulling forces for the ATP-channel are obviously
smaller than that for the allosteric-pocket-channel. The average
forces together with the integrated forces shown in Figure 6C and
Table 1 further clearly demonstrate that dissociation of imatinib is
easier along ATP-channel than allosteric-pocket-channel: the total
force required for the ligand to be extracted is 324 pN?ns, which is
16% smaller than that in allosteric-pocket-channel (384 pN?ns).
Intrinsic Reasons Why the Ligand Dissociation through
the ATP-Channel Is Favored
The above simulations clearly indicate that the ligand imatinib
dissociates from its binding protein kinases readily through the
ATP-channel rather than the allosteric-pocket-channel, irrespec-
tive of the receptor, initial structure, and the direction of pulling
force. Further, the simulation results also demonstrate that the
JMR that resides outside of the allosteric-pocket-channel is not a
factor that results in that the allosteric-pocket-channel is not
preferred. What are the determining factors leading to that the
ligand dissociation through the ATP-channel is favored? In order
to address this question, we analyzed the key components of
interaction energies between the ligand and protein kinases during
SMD simulations, including electrostatic, van de Waals (vdW), and
Figure 4. Force profiles of imatinib dissociation from imatinib-
c-Kit complex. (A) Force profile of imatinib unbinding along
traditional ATP-channel. (B) Force profile of imatinib unbinding along
allosteric-pocket-channel. (C) Averaged force profiles of imatinib
unbinding along ATP-channel (red) and allosteric-pocket-channel
(black).
doi:10.1371/journal.pone.0008470.g004
Table 1. Properties (maximum force and integrated force) of
the average forces suffered by imatinib during dissociation
processes along the ATP-channel and allosteric-pocket-
channel.
Maximum
force (pN)
integrated
force (pN?ns)
imatinib-c-Kit system ATP-channel 816 332
Allosteric-pocket-channel 1008 397
imatinib-Abl system ATP-channel 780 324
Allosteric-pocket-channel 830 384
doi:10.1371/journal.pone.0008470.t001
Figure 5. RMSD (root mean square deviation) profiles of key
motifs in imatinib-Abl complex during conventional molecular
dynamics simulation. The reference structure from which the RMSD
was calculated is the crystal structure 2HYY.
doi:10.1371/journal.pone.0008470.g005
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electrostatic and hydrogen-bonding interaction energy were very
similar for the both pathways (data not shown). These are
understandable due to the following reasons: (1) the ligand
imatinib is a very weak polar molecule, which results in that the
ligand suffers very similar electrostatic interaction when dissoci-
ating through different pathways; (2) hydrogen bonds are always in
the courses of breaking and forming in the ligand unbinding
process, and the overall number of hydrogen bonds keep relatively
invariable.
For the vdW interaction energy, however, obvious differences
could be found for these profiles along the ATP-channel and
allosteric-pocket-channel. Figure 7A presents the profiles of
average vdW interaction energy between imatinib and c-Kit
during dissociation through the two pathways. Obviously, there is
some fluctuation for both of the vdW energy profiles during the
SMD simulations. The highest vdW energy peak (the energy
barrier), however, is on the curve corresponding to the allosteric-
pocket-channel. The time point for the highest vdW energy peak is
around 0.4 ns, which is consistent with the time when the ligand
suffers the maximum pulling force (see Figure 4C). The vdW
interaction energy profiles for the imatinib-Abl system during
dissociation through ATP-channel and allosteric-pocket-channel
are shown in Figure 7B. Again, a fluctuation is observed for both
of the vdW energy curves during the SMD simulations. The
highest vdW energy peak (the energy barrier) occurs on the profile
corresponding to the allosteric-pocket-channel. The time point for
the highest vdW energy peak is around 0.3 ns, which is also
consistent with the time when the ligand suffers the maximum
pulling force (see Figure 6C).
The preceding energy analysis indicates that the difference of
vdW interaction energy is possibly a key factor determining that
the ligand dissociation through the ATP-channel is favored. But
what are the intrinsic reasons leading to the difference of vdW
interaction energies? In order to answer this question, we further
Figure 6. Force profiles of imatinib dissociation from imatinib-
Abl complex. (A) Force profile of imatinib unbinding along ATP-
channel. (B) Force profile of imatinib unbinding along allosteric-pocket-
channel. (C) Averaged force profiles of imatinib unbinding along ATP-
channel (red) and allosteric-pocket-channel (black).
doi:10.1371/journal.pone.0008470.g006
Figure 7. Energy profiles of van der Waals (vdW) interaction
between imatinib and its targeting kinases during dissociation.
(A) vdW interaction of imatinib-c-Kit system. (B) vdW interaction of
imatinib-Abl system. The vdW profiles shown in solid line are for the
ATP-channel and those shown in dotted line are for the allosteric-
pocket-channel.
doi:10.1371/journal.pone.0008470.g007
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allosteric-pocket-channel. Figure 8A and 8B present the variations
of RMSD values for the residues composing the ATP-channel and
allosteric-pocket-channel during the SMD simulations. Very
clearly, for both of the imatinib-c-Kit and imatinib-Abl model
systems, the variations of RMSD values for ATP-channel residues
are much larger than that for allosteric-pocket-channel, implying
that the residues forming the ATP-channel are more flexible than
that forming the allosteric-pocket-channel. These are consistent
with B-factor values experimentally measured [see crystal
structures of imatinib-c-Kit complex (PDB entry: 1T46) and
imatinib-Abl complex (PDB entry: 2HYY)]: the values of B-factor
for the residues forming the ATP-channel are generally larger than
that for the residues forming the allosteric-pocket-channel.
Further, the three-dimensional structures of ATP-channel and
allosteric-pocket-channel provide additional evidences: the resi-
dues forming the ATP-channel belong to certain b-sheet or loop,
nevertheless, in addition to b-sheets and loops, part of residues
composing the allosteric-pocket-channel also belong to the a-helix
(helix aC, see Figure 1). In general, flexibility of residues in a-helix
is smaller than that in b-sheet and loop.
Implications to the Development of Type II Kinase
Inhibitors
Finally, what implications to the development of type II protein
kinase inhibitors could be obtained from the present investigation?
As discussed above, the likelier dissociation pathway for the ligand
from its targeting kinases corresponds to the ATP-channel.
Rationally we can deduce that the ATP-channel would be also
preferred for the ligand association. This implies that, in the
association process of a type II kinase inhibitors, the hydrophobic
head of the inhibitor that is the motif locating in the allosteric
pocket, has to first pass through the ATP-channel and then the
allosteric-pocket-channel. It is clear that a bulky hydrophobic head
in type II kinase inhibitors is unfavorable. On the contrary, a bulky
polar tail in type II kinase inhibitors is allowed. These agree very
well with chemical structures of most of the known type II kinase
inhibitors that they often have a smaller hydrophobic head.
Several typical examples are shown in Figure 9.
In conclusion, molecular dynamics simulations reveal that the
most favorable pathway for imatinib dissociation corresponds to
the ATP-channel rather than the relatively wider allosteric-pocket-
channel, which is mainly due to the different van der Waals
interaction that the ligand suffers during dissociation. Neverthe-
less, the direct reason might come from the fact that the residues
composing the ATP-channel are more flexible than those forming
the allosteric-pocket-channel. This investigation, in addition to
clarify the dissociation mechanism of type II kinase inhibitor
imatinib from its targeting protein kinases, also suggests us that a
bulky hydrophobic head is unfavorable, but a large polar tail is
allowed for a potent type II inhibitor. The information obtained
here can be used to direct the discovery of type II kinase inhibitors.
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Figure 8. Variations of RMSD (root mean square deviation)
values for the residues composing the ATP-channel (solid line)
and allosteric-pocket-channel (dotted line) during the steered
molecular dynamics simulations. (A) is for imatinib-c-Kit system,
and (B) for imaintib-Abl system.
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Figure 9. Chemical structures of selected type II kinase
inhibitors. The substituent in dotted rectangle corresponds to the
head of inhibitor and that in solid rectangle corresponds to the tail of
inhibitor.
doi:10.1371/journal.pone.0008470.g009
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